Skip to main content

#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect

Jul 09, 2022 11:00 am
Social Author Name
Dr. John Cush
Tweet Content
#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷‍♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022 @Janetbirdope
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×